The Chairman, Medical Advisory Committee, University of Lagos, Dr Olufemi Fasanmade, has said that four million Nigerians are affected by diabetes.
Fasanmade stated this during the unveiling of Insulin Degludec, a once-daily basal insulin for the treatment of diabetes manufactured by Novo Nordisk Pharmaceuticals, last Friday at the Sheraton Hotel in Ikeja, Lagos.
He noted that more than half of the people living with diabetes in the country were not diagnosed because most often, diabetes, especially type 2, might not have any symptom.
Speaking on the mortality rate, Fasanmade emphasized that diabetes recorded a much higher death rate when compared to those who lost their lives to HIV, malaria, and tuberculosis combined.
“In the hospital where I work, about a third of the patients who come in with stroke, heart failure or kidney failure, have diabetes to blame for their conditions. So, it is a much bigger problem than malaria, HIV or tuberculosis,” Fasanmade said.
Also, a professor from the Division of Endocrinology and Diabetology at the Medical University of Graz, Austria, Thomas Pieber, said that maintaining good blood glucose control with insulin treatment could be challenging for healthcare professionals and patients due to concerns over low blood pressure.
He said, said that the symptoms of low blood sugar might include trembling, hunger, sweating, difficulty in concentrating, among others. “Severe low blood pressure may lead to seizure, coma and death.
Nocturnal low blood sugar is a real concern for people with diabetes as it is often unpredictable and unrecognised,”
The Corporate Vice-President, Novo Nordisk Pharmaceuticals, Mr Mads Bo Larsen Said “We have used it on our patients without low blood sugar. Compared to the previous basal insulin, the risk of low blood sugar is significantly less because of less reliability in its action,” Larsen said.